A Phase I Study of DZD2269 in Men with Advanced Prostate Cancer


Full Title

A Phase I, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Efficacy of DZD2269 in Patients with Metastatic Castration Resistant Prostate Cancer [DZ2109A0001]


Prostate cancers initially need the male hormone testosterone for growth. Hormone therapies that lower the level of testosterone are among the most effective treatments for prostate cancers that have spread to other organs (metastasized). The benefits of hormone treatments do not last, however. Over time, many prostate cancers continue to grow despite hormonal therapies; these are called “castration-resistant prostate cancers” (CRPC).

The purpose of this study is to find the highest dose of the investigational immunotherapy drug DZD2269 that can be given in men with CRPC. DZD2269 blocks adenosine, a molecule present in the cells and blood vessels around the tumor that can slow or stop the immune system’s response to cancer cells. Blocking adenosine releases the brakes on the immune system, enabling it to target and destroy cancer cells. DZD2269 is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have CRPC.
  • Patients should recover from the serious side effects of prior treatments before receiving DZD2269.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self-care, and capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for men age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Susan F. Slovin at 646-422-4470.